BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44:55-66. [PMID: 28361188 DOI: 10.1007/s00259-017-3687-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 12.2] [Reference Citation Analysis]
Number Citing Articles
1 Hunt S, Zandifar A, Alavi A. Molecular imaging in management of colorectal metastases by the interventional oncologist. International Journal of Hyperthermia 2022;39:675-81. [DOI: 10.1080/02656736.2021.1998657] [Reference Citation Analysis]
2 Sheikhbahaei S, Verde F, Hales RK, Rowe SP, Solnes LB. Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of 18F-FDG PET/CT. Clinical Lung Cancer 2020;21:485-97. [DOI: 10.1016/j.cllc.2020.06.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ferretti A, Chondrogiannis S, Rampin L, Bellan E, Marzola MC, Grassetto G, Gusella S, Maffione AM, Gava M, Rubello D. How to harmonize SUVs obtained by hybrid PET/CT scanners with and without point spread function correction. Phys Med Biol 2018;63:235010. [PMID: 30474620 DOI: 10.1088/1361-6560/aaee27] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Bastiaannet R, Lodge MA, de Jong HW, Lam MG. The Unique Role of Fluorodeoxyglucose-PET in Radioembolization. PET Clinics 2019;14:447-57. [DOI: 10.1016/j.cpet.2019.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mu J, Tian Y, Liu F, Wang Z, Tan R, Zhang B, Quan P, Zhang H, Yang J, Yuan P. Mitochondrial transcription factor B1 promotes the progression of hepatocellular carcinoma via enhancing aerobic glycolysis. J Cell Commun Signal 2021. [PMID: 34825289 DOI: 10.1007/s12079-021-00658-8] [Reference Citation Analysis]
6 Letellier A, Johnson AC, Kit NH, Savigny JF, Batalla A, Parienti JJ, Aide N. Uptake of Radium-223 Dichloride and Early [18F]NaF PET Response Are Driven by Baseline [18F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients. Mol Imaging Biol 2018;20:482-91. [PMID: 29027074 DOI: 10.1007/s11307-017-1132-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Lang D, Wahl G, Poier N, Graf S, Kiesl D, Lamprecht B, Gabriel M. Impact of PET/CT for Assessing Response to Immunotherapy-A Clinical Perspective. J Clin Med 2020;9:E3483. [PMID: 33126715 DOI: 10.3390/jcm9113483] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
8 Mattoli MV, Calcagni ML, Taralli S, Indovina L, Spottiswoode BS, Giordano A. How Often Do We Fail to Classify the Treatment Response with [18F]FDG PET/CT Acquired on Different Scanners? Data from Clinical Oncological Practice Using an Automatic Tool for SUV Harmonization. Mol Imaging Biol 2019;21:1210-9. [DOI: 10.1007/s11307-019-01342-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Gupta M, Choudhury PS, Jain P, Sharma M, Koyyala VPB, Goyal S, Agarwal C, Jajodia A, Pasricha S, Sharma A, Batra U. Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST? World J Nucl Med. [DOI: 10.1055/s-0042-1744201] [Reference Citation Analysis]
10 Porcu M, Solinas C, Garofalo P, de Azambuja E, Scartozzi M, Willard-Gallo K, Preusser M, Saba L. Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going? Crit Rev Oncol Hematol 2018;126:135-44. [PMID: 29759556 DOI: 10.1016/j.critrevonc.2018.03.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
11 Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB 2nd, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH Jr, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol 2019;14:1718-31. [PMID: 31470129 DOI: 10.1016/j.jtho.2019.08.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
12 Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G. FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. NPJ Breast Cancer 2021;7:125. [PMID: 34548493 DOI: 10.1038/s41523-021-00331-8] [Reference Citation Analysis]
13 Nicosia L, Cuccia F, Mazzola R, Figlia V, Giaj-Levra N, Ricchetti F, Rigo M, Bonù M, Corradini S, Tolia M, Alongi F. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. J Cancer Res Clin Oncol 2020;146:2351-8. [PMID: 32356176 DOI: 10.1007/s00432-020-03223-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 O JH, Lim SJ, Wang H, Leal JP, Shu HG, Wahl RL; QIN PET Readers. Quantitation of cancer treatment response by 2-[18F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™. EJNMMI Res 2021;11:15. [PMID: 33580383 DOI: 10.1186/s13550-021-00754-1] [Reference Citation Analysis]
15 Grimm J, Kiessling F, Pichler BJ. Quo Vadis, Molecular Imaging? J Nucl Med 2020;61:1428-34. [PMID: 32859706 DOI: 10.2967/jnumed.120.241984] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kuttner S, Lassen ML, Øen SK, Sundset R, Beyer T, Eikenes L. Quantitative PET/MR imaging of lung cancer in the presence of artifacts in the MR-based attenuation correction maps. Acta Radiol 2020;61:11-20. [PMID: 31091969 DOI: 10.1177/0284185119848118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Aide N, Fauchille P, Coquan E, Ferron G, Combe P, Meunier J, Alexandre J, Berton D, Leary A, De Rauglaudre G, Bonichon N, Pujade Lauraine E, Joly F. Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer. Eur J Nucl Med Mol Imaging 2021;48:1998-2008. [PMID: 33221969 DOI: 10.1007/s00259-020-05092-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Olin A, Ladefoged CN, Langer NH, Keller SH, Löfgren J, Hansen AE, Kjær A, Langer SW, Fischer BM, Andersen FL. Reproducibility of MR-Based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer. J Nucl Med 2018;59:999-1004. [PMID: 29123008 DOI: 10.2967/jnumed.117.198853] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kim DH, Yoo EH, Hong US, Kim JH, Ko YH, Moon SC, Cheon M, Yoo J. Image Registration of 18F-FDG PET/CT Using the MotionFree Algorithm and CT Protocols through Phantom Study and Clinical Evaluation. Healthcare (Basel) 2021;9:669. [PMID: 34199705 DOI: 10.3390/healthcare9060669] [Reference Citation Analysis]
20 Li MP, Kelly D, Tan J, Siva S, Kron T, David S. Single-fraction stereotactic ablative body radiotherapy for sternal metastases in oligometastatic breast cancer: Technique and single institution experience. J Med Imaging Radiat Oncol 2020;64:580-5. [PMID: 32588550 DOI: 10.1111/1754-9485.13075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Kishore SA, Drabkin MJ, Sofocleous CT. Fluorodeoxyglucose-PET for Ablation Treatment Planning, Intraprocedural Monitoring, and Response. PET Clin 2019;14:427-36. [PMID: 31472740 DOI: 10.1016/j.cpet.2019.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Mankoff DA, Pantel AR, Viswanath V, Karp JS. Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology. Curr Pathobiol Rep 2019;7:97-108. [DOI: 10.1007/s40139-019-00202-9] [Cited by in Crossref: 9] [Article Influence: 3.0] [Reference Citation Analysis]
23 Park HL, Han EJ, O JH, Choi BO, Park G, Jung SE, Yahng SA, Eom KS, Cho SG, On Behalf Of Catholic University Lymphoma Group. Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma. Diagnostics (Basel) 2020;10:E1002. [PMID: 33255487 DOI: 10.3390/diagnostics10121002] [Reference Citation Analysis]
24 Langer NH, Langer SW, Johannesen HH, Hansen AE, Costa J, Klausen TL, Forman J, Olin A, Rasmussen SH, Sørensen JB, Löfgren J, Kjær A, Fischer BM. Very Early Response Evaluation by PET/MR in Patients with Lung Cancer-Timing and Feasibility. Diagnostics (Basel) 2019;9:E35. [PMID: 30917539 DOI: 10.3390/diagnostics9010035] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, Oprea-Lager DE, Oyen WJ, Rouvière O, Mottet N, Bjartell A. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 2021;48:469-76. [PMID: 32617640 DOI: 10.1007/s00259-020-04934-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
26 Rossi S, Castello A, Toschi L, Lopci E. Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. Immunotherapy 2018;10:797-805. [DOI: 10.2217/imt-2017-0187] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
27 Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging 2017;44:2310-25. [PMID: 28815334 DOI: 10.1007/s00259-017-3802-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
28 Castello A, Grizzi F, Qehajaj D, Rahal D, Lutman F, Lopci E. 18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. Leuk Lymphoma 2019;60:367-75. [PMID: 30032683 DOI: 10.1080/10428194.2018.1488254] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
29 Aide N, Fanti S. Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community. Eur J Nucl Med Mol Imaging 2017;44:1-3. [PMID: 28540418 DOI: 10.1007/s00259-017-3721-5] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
30 Switlyk MD. Magnetic resonance imaging for assessing treatment response in bone marrow metastases. Acta Radiol 2021;62:483-99. [PMID: 31154803 DOI: 10.1177/0284185119851234] [Reference Citation Analysis]
31 Turgeon GA, Iravani A, Akhurst T, Beaulieu A, Callahan JW, Bressel M, Cole AJ, Everitt SJ, Siva S, Hicks RJ, Ball DL, Mac Manus MP. What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria? J Nucl Med 2019;60:328-34. [PMID: 30030343 DOI: 10.2967/jnumed.118.214148] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
32 Prigent K, Aide N. 18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects: A Checklist for the PET Reader. PET Clin 2020;15:1-10. [PMID: 31735296 DOI: 10.1016/j.cpet.2019.08.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
33 Acar E, Özdoğan Ö, Aksu A, Derebek E, Bekiş R, Çapa Kaya G. The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival. Ann Nucl Med 2019;33:681-8. [PMID: 31214958 DOI: 10.1007/s12149-019-01376-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
34 Maghsoomi Z, Emami Z, Malboosbaf R, Malek M, Khamseh ME. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC Cancer 2021;21:579. [PMID: 34016077 DOI: 10.1186/s12885-021-08257-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kumar N, Deo S, Bhoriwal S, Sharma A, Pramanik R, Kumar R, Das P, Arora S, Kumar S. Comparison of treatment response assessed by 18F-FDG PET/CT with the histopathological response using tumor regression grading on surgically resected specimen following neoadjuvant chemotherapy in squamous cell carcinoma of esophagus. Nucl Med Commun 2021;42:928-34. [PMID: 33795613 DOI: 10.1097/MNM.0000000000001413] [Reference Citation Analysis]
36 Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019;9:8. [PMID: 30694399 DOI: 10.1186/s13550-019-0473-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 13.7] [Reference Citation Analysis]
37 Damaraju VL, Aminpour M, Kuzma M, Winter P, Preto J, Tuszynski J, McEwan ABJ, Sawyer MB. Tyrosine Kinase Inhibitors Reduce Glucose Uptake by Binding to an Exofacial Site on hGLUT-1: Influence on 18 F-FDG PET Uptake. Clin Transl Sci 2021;14:847-58. [PMID: 33278334 DOI: 10.1111/cts.12943] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Lee YYD, Nguyen DT, Moodie T, O'Brien R, McMaster A, Hickey A, Pritchard N, Poulsen P, Tabaksblat EM, Weber B, Worm E, Pryor D, Chu J, Hardcastle N, Booth J, Gebski V, Wang T, Keall P. Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring. BMC Cancer 2021;21:494. [PMID: 33941111 DOI: 10.1186/s12885-021-08184-x] [Reference Citation Analysis]
39 Helland F, Hallin Henriksen M, Gerke O, Vogsen M, Høilund-Carlsen PF, Hildebrandt MG. FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review. Diagnostics (Basel) 2019;9:E106. [PMID: 31461923 DOI: 10.3390/diagnostics9030106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
40 Lee DY, Kim YI. Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer: A Meta-analysis. Clin Nucl Med 2020;45:604-10. [PMID: 32520503 DOI: 10.1097/RLU.0000000000003110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
41 Voigt W. Advanced PET imaging in oncology: status and developments with current and future relevance to lung cancer care. Curr Opin Oncol 2018;30:77-83. [PMID: 29251666 DOI: 10.1097/CCO.0000000000000430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Lasnon C, Coudrais N, Houdu B, Nganoa C, Salomon T, Enilorac B, Aide N. How fast can we scan patients with modern (digital) PET/CT systems? Eur J Radiol 2020;129:109144. [PMID: 32593080 DOI: 10.1016/j.ejrad.2020.109144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
43 Ingenerf M, Kiesl S, Karim S, Beyer L, Ilhan H, Rübenthaler J, Seidensticker M, Ricke J, Schmid-Tannwald C. 68Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE). Cancers (Basel) 2021;13:4321. [PMID: 34503131 DOI: 10.3390/cancers13174321] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Aykan NF, Özatlı T. Objective response rate assessment in oncology: Current situation and future expectations. World J Clin Oncol 2020; 11(2): 53-73 [PMID: 32133275 DOI: 10.5306/wjco.v11.i2.53] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
45 Lian W, Liu C, Gu B, Zhang J, Lu L, Pan H, Yao Z, Wang M, Song S, Zhang Y, Yang Z. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer. Nucl Med Commun 2020;41:280-7. [PMID: 32032193 DOI: 10.1097/MNM.0000000000001145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Mottaghy FM. Is the whole larger than the sum of the parts? Integrated PET/MRI as a tool for response prediction. Eur J Nucl Med Mol Imaging 2018;45:325-7. [PMID: 29279944 DOI: 10.1007/s00259-017-3908-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
47 Castello A, Lopci E. Update on tumor metabolism and patterns of response to immunotherapy. Q J Nucl Med Mol Imaging 2020;64. [DOI: 10.23736/s1824-4785.20.03251-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Fonti R, Conson M, Del Vecchio S. PET/CT in radiation oncology. Semin Oncol 2019;46:202-9. [PMID: 31378377 DOI: 10.1053/j.seminoncol.2019.07.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
49 Ayoub M, Eleneen Y, Colen RR. Cancer Imaging in Immunotherapy. Adv Exp Med Biol 2020;1244:309-24. [PMID: 32301025 DOI: 10.1007/978-3-030-41008-7_18] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Castello A, Lopci E. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. Curr Radiopharm 2020;13:24-31. [PMID: 31749440 DOI: 10.2174/1874471012666191015100106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
51 Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019;14:437-45. [DOI: 10.1016/j.cpet.2019.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Frega S, Dal Maso A, Pasello G, Cuppari L, Bonanno L, Conte P, Evangelista L. Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers (Basel) 2020;12:E1303. [PMID: 32455666 DOI: 10.3390/cancers12051303] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 Nakamura M, Satake H, Sagawa T, Takagane A, Sekikawa T, Oguchi K, Kaji T, Takeuchi M, Ichikawa W, Fujii M. 18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12). Oncol Ther 2021;9:635-45. [PMID: 34626349 DOI: 10.1007/s40487-021-00173-1] [Reference Citation Analysis]
54 Viglianti BL, Wale DJ, Wong KK, Johnson TD, Ky C, Frey KA, Gross MD. Effects of Tumor Burden on Reference Tissue Standardized Uptake for PET Imaging: Modification of PERCIST Criteria. Radiology 2018;287:993-1002. [PMID: 29558296 DOI: 10.1148/radiol.2018171356] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
55 Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging 2017;44:17-31. [PMID: 28623376 DOI: 10.1007/s00259-017-3740-2] [Cited by in Crossref: 120] [Cited by in F6Publishing: 106] [Article Influence: 24.0] [Reference Citation Analysis]
56 Delgado Bolton RC, Aide N, Colletti PM, Ferrero A, Paez D, Skanjeti A, Giammarile F. EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA). Eur J Nucl Med Mol Imaging 2021;48:3286-302. [PMID: 34215923 DOI: 10.1007/s00259-021-05450-9] [Reference Citation Analysis]
57 Franzese C, Comito T, Viganò L, Pedicini V, Franceschini D, Clerici E, Loi M, Donadon M, Poretti D, Solbiati L, Torzilli G, Scorsetti M. Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer. Clin Breast Cancer 2020;20:480-6. [PMID: 32631769 DOI: 10.1016/j.clbc.2020.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
58 Donegani MI, Ferrarazzo G, Marra S, Miceli A, Raffa S, Bauckneht M, Morbelli S. Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology. Medicina (Kaunas) 2020;56:E373. [PMID: 32722205 DOI: 10.3390/medicina56080373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
59 Ryu WK, Kim JS, Park MH, Lee M, Kim HJ, Ryu JS, Lim JH. Heterogeneous radiological response to chemotherapy is associated with poor prognosis in advanced non-small-cell lung cancer. Thorac Cancer 2021. [PMID: 34693646 DOI: 10.1111/1759-7714.14207] [Reference Citation Analysis]
60 Dourado MLC, Dompieri LT, Leitão GM, Mourato FA, Santos RGG, Almeida PJ, Markman B, Melo MDT, Brandão SCS. Aumento de Captação Cardíaca de 18F-FDG Induzida por Quimioterapia em Pacientes com Linfoma: Um Marcador Precoce de Cardiotoxicidade? Arquivos Brasileiros de Cardiologia 2022. [DOI: 10.36660/abc.20210463] [Reference Citation Analysis]
61 Sørensen JS, Vilstrup MH, Holm J, Vogsen M, Bülow JL, Ljungstrøm L, Braad PE, Gerke O, Hildebrandt MG. Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer. Diagnostics (Basel) 2020;10:E1001. [PMID: 33255442 DOI: 10.3390/diagnostics10121001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Dolci C, Spadavecchia C, Crivellaro C, De Ponti E, Todde S, Morzenti S, Turolla EA, Crespi A, Guerra L, Landoni C. Treatment response assessment in [18F]FDG-PET/CT oncology scans: Impact of count statistics variation and reconstruction protocol. Phys Med 2019;57:177-82. [PMID: 30738523 DOI: 10.1016/j.ejmp.2018.12.038] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Costa LB, Queiroz MA, Barbosa FG, Nunes RF, Zaniboni EC, Ruiz MM, Jardim D, Gomes Marin JF, Cerri GG, Buchpiguel CA. Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. Radiographics 2021;41:120-43. [PMID: 33275541 DOI: 10.1148/rg.2021200093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]